Mon.Jan 23, 2023

article thumbnail

Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

Bio Pharma Dive

This year could stay turbulent for the biotech sector as investors look for what the Roivant CEO described in an interview with BioPharma Dive as “safe harbors in a storm &rdquo

278
278
article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

Systemic lupus erythematosus (SLE) is a systemic, inflammatory, chronic autoimmune disease that can affect multiple organs simultaneously or sequentially, with a relapsing and remitting nature.

Marketing 229
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pliant shares jump on new data for lung disease drug

Bio Pharma Dive

A high dose of the company’s experimental medicine appeared potent in patients with idiopathic pulmonary fibrosis, an elusive target for drugmakers. The results are from a small and short clinical trial, however

article thumbnail

Pharma Mirror Q&A with Jane Myles, Vice President of Clinical Trial Innovation at Curebase

Pharma Mirror

The White House Office of Science & Technology Policy (OSTP) convened a listening session January 11.

article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

article thumbnail

FDA weighs shift in COVID vaccination strategy

Bio Pharma Dive

Agency scientists are proposing to update COVID shots once a year to match circulating coronavirus strains, as well as simplifying current vaccination regimens

Scientist 256
article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

In recent years, with the advent of biologics and novel therapeutic targets such as anti-TNF, anti-interleukin, and anti-integrin, there has been a steady increase in the number of agents approved to treat inflammatory bowel diseases (IBD), which has provided physicians with an increasing number of options to treat Crohn’s disease (CD).

More Trending

article thumbnail

Takeda signs licensing agreement with HUTCHMED for fruquintinib

Pharmaceutical Technology

Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter’s fruquintinib.

Licensing 130
article thumbnail

How CAR-T therapies are revolutionizing cancer treatments

Bio Pharma Dive

One of the most significant advancements made in treating disease in recent years is the development and commercialization of CAR-T therapy, which weaponizes a patient’s own white blood cells to attack certain types of blood cancer cells

article thumbnail

Disc and Mabwell sign deal for licence to antibodies portfolio

Pharmaceutical Technology

Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis.

Antibody 130
article thumbnail

Takeda pays $400M to buy into Hutchmed’s colorectal cancer drug

Bio Pharma Dive

The deal is the second big licensing deal Takeda has signed in as many months and gives the company rights to a drug Hutchmed began submitting to U.S. regulators in December

Licensing 153
article thumbnail

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

article thumbnail

First patients enrolled for Priothera’s mocravimod trial

Pharma Times

Treatment is a maintenance therapy for certain patients with acute myeloid leukaemia

Trials 109
article thumbnail

Charles River and Rznomics pair up on gene therapy development, Chinese CDMO lands $220m Series C funding

BioPharma Reporter

Charles River Laboratories International, Inc and Rznomics Inc, a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have established a viral vector contract development and manufacturing organization (CDMO) partnership. Markets & Regulations

RNA 91
article thumbnail

OxSonics trial produces positive SonoTran data

Pharma Times

During the research SonoTran is being evaluated in patients with metastatic colorectal cancer

article thumbnail

Takeda pledges up to $1.13B for rights to Hutchmed's cancer drug fruquintinib outside of China

Fierce Pharma

Takeda pledges up to $1.13B for rights to Hutchmed's cancer drug fruquintinib outside of China kdunleavy Mon, 01/23/2023 - 09:49

Drugs 83
article thumbnail

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

article thumbnail

Apex gets approval for ‘world’s largest’ take home psychedelic trial

Outsourcing Pharma

The company plans to conduct a Phase 2b trial to test its APEX-52 psilocybin drug candidate to treat adults with post-traumatic stress disorder. Clinical Development

Drugs 82
article thumbnail

Bayer chairman under fire for lack of spinoff activity amid renewed investor activism

Fierce Pharma

Bayer chairman under fire for lack of spinoff activity amid renewed investor activism aliu Mon, 01/23/2023 - 09:46

83
article thumbnail

Under FDORA, FDA to Require Most Drug and Device Trials to Submit Diversity Action Plans

The FDA Law Blog

By Faraz Siddiqui & Deborah L.

article thumbnail

A glance back to Pharma Integrates, London 2022 – part iii

Pharma Phorum

Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022.

article thumbnail

TTP Reveals New Cell and Gene Therapy Organization

Pharmaceutical Commerce

Creates Cellular Origins in order to simplify the late-stage development process us

article thumbnail

Monkeypox: Disease Overview, Transmission and Diagnosis

Roots Analysis

Monkeypox is a viral disease, which is usually transmitted to humans from animals. The disease is known to have symptoms similar to those observed in smallpox patients, although it is considered to be clinically less severe.

article thumbnail

Informa Connect’s PAP – Patient Assistance & Access Programs | Part of Access USA

Drug Channels

Informa Connect’s PAP – Patient Assistance & Access Programs | Part of Access USA Hybrid Event | March 20-22, 2023, Philadelphia Marriott Downtown www.informaconnect/pap Exclusive Offer – Be sure to use your exclusive promocode 23DCPAP10 to save 10% off* your registration.

Drugs 65
article thumbnail

Big Pharma set for more Senate scrutiny as Democrats eye pricing, tax probes: report

Fierce Pharma

Big Pharma set for more Senate scrutiny as Democrats eye pricing, tax probes: report fkansteiner Mon, 01/23/2023 - 14:30

63
article thumbnail

Movie motion capture tech tested for disease tracking

Pharma Phorum

Motion capture technology used to bring fantasy characters to life in movies like Avatar and The Lord of the Rings is being used alongside artificial intelligence (AI) to track diseases that lead to disorders of movement.

Gene 56
article thumbnail

Call for nominations: The most influential people in biopharma in 2023

Fierce Pharma

Call for nominations: The most influential people in biopharma in 2023 esagonowsky Mon, 01/23/2023 - 14:32

52
article thumbnail

Upperton breaks ground on £15m manufacturing facility

Outsourcing Pharma

A UK CDMO has started work on the construction of its development and GMP manufacturing headquarters in Nottingham, UK. Contract Manufacturing & Logistics

article thumbnail

Pharmacovigilance - Indian view of 2023

Pharma Tutor

Pharmacovigilance - Indian view of 2023 admin Tue, 01/24/2023 - 12:26 Pharmacovigilance is the process of monitoring and assessing the safety of medications after they have been approved and are on the market.

article thumbnail

New patent expiration for Ge Healthcare drug VIZAMYL

Drug Patent Watch

Annual Drug Patent Expirations for VIZAMYL Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. It is available from one supplier. There are five patents… The post New patent expiration for Ge Healthcare drug VIZAMYL appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

With TheracosBio green light, another SGLT2 inhibitor wades into diabetes arena

Fierce Pharma

With TheracosBio green light, another SGLT2 inhibitor wades into diabetes arena fkansteiner Mon, 01/23/2023 - 09:16

52
article thumbnail

New patent for Deciphera Pharms drug QINLOCK

Drug Patent Watch

Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. It is available from one supplier. There are ten patents… The post New patent for Deciphera Pharms drug QINLOCK appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Jazz swings on ASCO-GI data for zanidatamab

Pharma Phorum

Jazz Pharma’s $325 million gamble on rights to Zymeworks’ HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout at the ASCO-GI 2023 congress.

article thumbnail

Hired and retired: New appointments in the biopharma industry

BioPharma Reporter

Moderna, Novavax and Biogen are among the companies welcoming new faces to top jobs this month. Biopharma Culture

52
article thumbnail

ASCO-GI data sets up wider use of Ipsen’s Onivyde

Pharma Phorum

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023 congress.

Sales 52
article thumbnail

Phesi: Long-term damage from COVID-19 movement restrictions on clinical development is becoming clearer

BioPharma Reporter

Phesi led analysis reveals an overall decrease in the number of recruiting trials and higher proportion of Phase 2 terminations in 2022. Markets & Regulations

Trials 52
article thumbnail

BeiGene’s Brukinsa FDA approved for CLL/SLL

Pharma Phorum

Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). CLL is a common form of leukaemia and accounts for roughly 25% of all new cases each year.